What changed in policy—or in our evidence—and how the pathway changed

Section 130b(7a) permits either party to terminate agreements or arbitration awards establishing reimbursement amounts by 29 July 2026, by the end of 1 October 2026. This includes medicines no longer marketed in Germany. A replacement must be agreed without delay; the old agreement remains in effect until the new one takes effect.

Added a dated checkpoint to negotiation and legacy-contract review. This is an Atlas clarification of the existing law, not a new September policy or an automatic termination of every agreement.

The Commission's 19 August guidance clarifies early information for products within JCA scope: declare scope in the EMA Eligibility and Letter of Intent forms, notify the HTA Secretariat in parallel, and upload the forms using a product-specific platform link. Changes to the planned submission date or withdrawal must also be communicated.

Added the parallel JCA/EMA pre-submission handoff to the regulatory decision's operating detail in the 14 EU markets covered by Atlas. This is a shared EU preparation step; national assessment, pricing and reimbursement decisions remain distinct.

NMPA Announcement No. 50 of 2026, dated 21 May and published 8 June 2026, brings the revised Good Clinical Practice standard into effect on 1 September 2026 and repeals the 2020 standard. It makes participant rights, safety and wellbeing paramount and requires quality by design, identification of critical quality factors, proportionate quality management, reliable and traceable data, fit-for-purpose computerized systems, and auditable duties across sponsors, investigators, institutions, ethics committees, laboratories and contracted service providers.

Atlas now treats current-GCP compliance as an upstream clinical-evidence and lifecycle gate before marketing authorization. The transition can affect trial initiation, conduct, change control, safety reporting, suspension or termination and the acceptability of the final authorization dossier; it does not itself create reimbursement. The official announcement date is 21 May 2026, publication date 8 June and effective date 1 September; the separate Atlas content-update date is 4 September 2026.

NICE published interim methods statement PMG51 on 27 August 2026. For technology appraisals and highly specialised technologies with an invitation to participate issued after publication, adult reference-case analyses must use the EQ-5D-5L descriptive system and the new UK 5L value set. Available 3L data must be mapped to 5L; 3L value-set utilities are not accepted as new-topic sensitivity scenarios. Topics already underway retain the former 5L-to-3L approach, and published guidance is not reopened solely for this change.

Atlas now makes the NICE topic start date an evidence-method gate, shows the required 5L value set and 3L-to-5L mapping direction for new topics, and preserves the prior method for ongoing topics. The official policy date is 27 August 2026; the separate Atlas content-update date is 28 August 2026.

ALPS now requires every awarded supplier to register on SAP Business Network and accept the Trading Relationship Request issued through the relevant PHI purchase order before transacting or invoicing. The sole-platform rollout started for Woodlands Health and Alexandra Hospital on 3 August 2026, expanded to NHG, NUHS, Synapxe, AIC and 1FSS on 17 August, and is scheduled for SingHealth and ALPS in January 2027.

Atlas now separates contract award and stock from supplier-network enablement, PO-linked relationship acceptance and a payable electronic invoice. A funded and delivered medicine can still fail the procurement-to-payment flow if this gate is not active.

Portaria GM/MS 12.085, dated 17 August 2026 and posted by the Ministry on 18 August, establishes minimum structure, organisation and responsibility requirements for centres that dilute ultra-high-cost oncology medicines and adds a specialised-service classification to CNES.

Atlas now treats AF-ONCO list status, acquisition modality, qualified dilution-site CNES status and treating-centre readiness as separate execution gates. The ordinance date is not being presented as evidence that every centre is already qualified.

Decree-Law 118/2026 was published on 17 June and entered into force on 1 July 2026, replacing the former SiNATS decree-law. It integrates applicable EU joint clinical assessments into the national evidence flow and creates a voluntary three-year pilot for coordinated AIM and public-funding assessment while retaining separate regulatory and financing decisions.

Atlas now uses Decree-Law 118/2026 as the controlling legal basis, shows EU clinical assessment as an input rather than Portugal's final value decision, and adds an optional parallel-assessment branch whose regulatory and funding outputs remain separate.

The current SGB V text effective from 30 July 2026 requires §130b agreements to address price and volume. If the parties do not agree a rule, a statutory annual adjustment can apply from year four. The reform also replaces the former §130e combination-discount mechanism with sickness-fund contracts for therapeutically comparable patent-protected medicine groups, and removes nationwide Praxisbesonderheit treatment from new §130b agreements while preserving defined legacy arrangements.

Atlas now separates the month-seven reimbursement amount from later price-volume adjustment and fund-specific patent-group contracting. Outpatient prescribing also distinguishes the legacy nationwide practice exception from the new contract-based economic-review treatment.

The PBS Ministerial-discretion page updated on 12 August 2026 confirms 5% reductions at the fifth and tenth anniversaries and a fifteenth-anniversary reduction of 26.1%, increasing to 30% from 1 April 2027. It also specifies the first-new-brand reduction formula, flow-on rules and the HPP request timetable for the April 2027 reduction day.

Atlas now shows the exact anniversary reductions, the first generic or biosimilar floor formula, same-drug/mechanism flow-on and the fact that Ministerial discretion requires a timed HPP request rather than creating an automatic exemption.

No new official Chinese policy was published on 6 August. Atlas revised the pathway on that date after reviewing existing NHSA material on the 2026 catalogue cycle. The latest cited official source was published on 31 May 2026.

The China pathway now distinguishes formal NRDL submission, expert review, national negotiation or bidding, agreement-period management and later VBP/follow-on procurement instead of treating reimbursement as one listing event.

The Health Insurance Policy Deliberation Committee approved pharmaceutical-pricing reforms that expand flexible price contracting and reinforce reassessment and lifecycle price management.

The Korea pathway now separates HIRA reimbursement assessment, RSA/CEA-exemption eligibility, NHIS price or contract negotiation, flexible-contract handling and later use-volume/reassessment events.

The Ministry of Health published the AF-ONCO framework and 2026 amendments for organising financing, acquisition, distribution and dispensing of selected high-cost oncology medicines.

The Brazil pathway now distinguishes conventional PCDT/APAC centre financing from AF-ONCO selection, central acquisition/distribution and local dispensing. APAC remains a Brazilian oncology authorisation/payment instrument—not the Asia-Pacific region.

Royal Decree 415/2026 established the national health-technology assessment framework, including separate clinical and non-clinical phases, procedural clocks and transition arrangements.

The Spain pathway now separates the evolving national HTA phases from the later CIPM financing/price decision and from autonomous-community or hospital implementation. The HTA output is evidence input; it is not itself the reimbursement decision.

Belgium's Early and Fast Access framework became effective on 1 March 2026, creating an earlier route for eligible medicines and patients while the routine price-and-reimbursement process continues.

The Belgium pathway now shows EEFA eligibility and patient intervention as a distinct branch rather than folding it into routine CRM/CTG reimbursement or Article 81/111 temporary agreements.